Autosomal Recessive Congenital Ichthyosis 5 (ARCI-5)

Autosomal Recessive Congenital Ichthyosis 5 (ARCI-5) is a rare, inherited skin condition that starts at birth or soon after. It makes the skin dry, thick, and scaly all over the body. ARCI-5 happens when both copies of a gene called CYP4F22 do not work properly. This gene helps the skin build a strong “water-proofing” barrier using special fats called acylceramides. When CYP4F22 is faulty, the skin cannot make enough acylceramides. The outer skin layer then leaks water, becomes very dry, cracks easily, and allows germs and irritants to enter. That is why people with ARCI-5 often have scaling, redness, and infections. ARCI-5 is “autosomal recessive,” which means a child is affected only if they inherit one non-working gene from each parent; carriers (with one changed gene) are usually healthy. NCBI+2PubMed Central+2

ARCI5 is a lifelong, inherited skin condition that runs in families in an autosomal recessive way. Babies are often born with a tight, shiny “collodion” covering over the skin. Later, the skin becomes very dry and scaly over most of the body. The redness can vary. The main problem is a weak skin barrier, so water escapes too fast and the skin loses its normal protection. This weak barrier makes the skin crack, itch, and get infections more easily. NCBI

This gene helps make special skin lipids called acylceramides that are essential for a strong outer skin layer. When CYP4F22 does not work well, the skin cannot build a tight seal, so scaling and dryness happen. CYP4F22–related ichthyosis is recognized as ARCI type 5 in medical genetics. PubMed Central+2genecards.org+2

CYP4F22’s normal job is to add a tiny chemical “handle” (ω-hydroxyl group) to very-long-chain fatty acids. This step is essential to make acylceramides, the key building blocks of the skin’s outer “lipid mortar.” Without this step, the mortar is weak and the “bricks” (skin cells) cannot seal tightly. The result is the classic look and feel of ichthyosis (generalized scale and sometimes redness). PubMed Central+2PubMed+2

Other names

• CYP4F22-related ARCI

• Lamellar ichthyosis due to CYP4F22 (some patients have a lamellar ichthyosis pattern)

• ARCI type 5 (ARCI-5)
  These terms all point to the same disease mechanism: pathogenic variants in CYP4F22. PubMed Central+1

Types

ARCI is a family of conditions with many genes. Within this family, ARCI-5 is the form caused by CYP4F22. The outward appearance (phenotype) can vary between people with the same gene, so doctors often describe clinical “types” by how the skin looks: NCBI

1. Lamellar ichthyosis pattern – large, plate-like scales with minimal redness. Common in CYP4F22 disease. PubMed Central

2. Congenital ichthyosiform erythroderma pattern – finer scale with more red skin. This can also occur in CYP4F22 disease. Orpha.net

3. Collodion baby at birth – some newborns are covered with a tight, shiny membrane that peels off. (This is a presentation seen across ARCI genes, including CYP4F22.) NCBI

Key point: “Types” here describe how it looks, not different genes. The gene for ARCI-5 is always CYP4F22, but the skin picture can range from plate-like scales to red, finely scaling skin. NCBI

Causes

The single root cause of ARCI-5 is a harmful change (pathogenic variant) in both copies of the CYP4F22 gene. Everything else below either explains how that cause works, the kinds of genetic changes that can do it, or factors that can modify severity. I’m listing 20 clearly, but remember: the disease itself is genetic. PubMed Central+1

1. Pathogenic CYP4F22 variants (two copies) – Required for ARCI-5. Missense, nonsense, splice-site, frameshift, or deletions can all cause loss of function. PubMed Central+1

2. Missense variants – One amino-acid change can make the enzyme fold poorly or stop working. Lippincott Journals

3. Nonsense/frameshift variants – Early “stop” signals or shifts that truncate CYP4F22. PubMed Central

4. Splice-site variants – Disrupt normal RNA splicing, producing nonfunctional enzyme. PubMed Central

5. Exonic deletions/duplications – Remove or repeat gene segments and break enzyme activity. PubMed Central

6. Compound heterozygosity – Two different harmful variants (one from each parent). NCBI

7. Consanguinity (parents related) – Raises the chance both parents carry the same rare variant. This affects risk, not severity. Nature

8. Founder effects in certain populations – Some groups share old variants that increase local frequency. PubMed Central

9. Defective ω-hydroxylation step – Mechanism: enzyme cannot add the ω-OH to ultra-long fatty acids. PubMed Central

10. Low acylceramide production – Without ω-OH, acylceramides drop and the barrier fails. PubMed Central

11. Weak corneocyte lipid envelope (CLE) – Acylceramides help build the CLE; poor CLE weakens barrier. FEBS Journal

12. Secondary skin water loss (TEWL) – Leaky barrier causes high water loss, dryness, and scale. FEBS Journal

13. Micro-inflammation from barrier break – Irritants and microbes can enter and trigger redness. (Mechanistic inference based on barrier science.) FEBS Journal

14. Environmental dryness/cold – Not a cause of ARCI-5, but worsens dryness and scaling. (Modifier.) (General barrier science.) FEBS Journal

15. Frequent bathing with harsh soaps – Strips lipids and aggravates barrier weakness. (Modifier.) FEBS Journal

16. Skin infections – Common in barrier disorders; infections can worsen redness and scale. (Modifier.) NCBI

17. Heat and sweating issues – Thick scale can impair sweating and lead to overheating. (Modifier.) NCBI

18. Friction/pressure areas – Scale builds and cracks at elbows, knees, and over joints. (Modifier.) NCBI

19. Malnutrition or low essential fatty acids – Doesn’t cause ARCI-5, but can worsen barrier function and healing. (Modifier; nutrition-barrier link.) FEBS Journal

20. Other lipid-pathway gene variation – Very rarely, variants in related lipid enzymes may modify severity (e.g., ELOVL4, CERS3, PNPLA1 pathway context). (Modifier concept drawn from acylceramide pathway literature.) PubMed Central

Symptoms

1. Generalized dry, scaly skin – Most or all of the body shows persistent scaling because the outer barrier leaks water. NCBI

2. Thick “plate-like” or fine scale – Some have big brown plates (lamellar pattern); others have finer white scale with redness. NCBI+1

3. Redness (erythroderma) – Ongoing irritation from a weak barrier makes the skin look red, especially in infancy. NCBI

4. Cracks and fissures – Dry, tight skin splits, especially on hands, feet, and flexing areas; this can be painful. NCBI

5. Itch – Dryness and micro-inflammation create itching that can disturb sleep. NCBI

6. Newborn “collodion” membrane – Some babies are born with a shiny sheath that peels over days. NCBI

7. Tight skin (ectropion/eclabium possible) – The skin can pull eyelids outward and lips back in severe newborn cases. NCBI

8. Heat intolerance – Thick scale can block sweat and make overheating more likely. NCBI

9. Recurrent skin infections – Cracks and poor barrier let bacteria or fungi in more easily. NCBI

10. Palmar and plantar thickening – Hands and feet can develop thicker skin and deep lines. NCBI

11. Scaling on scalp – Thick scalp scale may look like stubborn dandruff. NCBI

12. Nail changes – Nails may become thick, brittle, or ridged from ongoing inflammation. NCBI

13. Eye irritation – Ectropion and dryness can irritate the eyes; lubrication is often needed. NCBI

14. Dehydration risk in infants – High water loss across skin can lead to dehydration if care is not optimized. NCBI

15. Psychosocial stress – Visible scaling can affect confidence and social comfort; support helps. NCBI

Diagnostic tests

A) Physical examination (bedside observation)

1. Full-body skin exam – A dermatologist looks at scale size, color, distribution, and redness to recognize ARCI patterns and rule out other causes. NCBI

2. Newborn assessment for collodion – In the first days, clinicians look for a shiny membrane, tight eyelids/lips, and early complications. NCBI

3. Nail, scalp, and mucosal check – The doctor checks the nails, scalp scale, mouth, and eyes for dryness or pull-back of lids. NCBI

4. Palms/soles thickness check – Palmar-plantar thickening and fissures are documented, which helps with severity grading. NCBI

5. Infection screening on exam – Redness, crusting, and tenderness may suggest secondary infection that needs treatment. NCBI

B) “Manual or simple bedside tests (non-lab tools used in clinic)

6. Hydration scoring by feel/visual scale – Clinicians estimate dryness and scaling using standardized visual scales to track response over time. NCBI

7. Emollient response test – Short, supervised trial of thick moisturizers or keratolytics can show how much scale is “mechanical” vs structural. (Clinical practice concept.) NCBI

8. Gentle scale removal assessment – Soak-and-soften method helps gauge scale bonding strength and guides home care plans. (Clinical practice concept.) NCBI

9. Skin pH measurement (handheld meter) – Slightly acidic skin is healthier; pH meters help track barrier micro-environment. (Barrier metrics concept.) FEBS Journal

10. TEWL spot-check (trans-epidermal water loss) – A handheld device measures water escaping through skin; TEWL is often high in ARCI. FEBS Journal

C) Laboratory and pathological tests

11. Genetic testing (targeted gene panel) – The most important test: detects CYP4F22 variants and other ARCI genes; confirms ARCI-5 when both CYP4F22 alleles are pathogenic. NCBI

12. Whole-exome/whole-genome sequencing – Used if panel is negative; can find rare or novel CYP4F22 variants and deep intronic changes. NCBI

13. Variant classification (ClinVar/ACMG) – Labs classify variants (pathogenic/likely pathogenic/etc.) and may reference ClinVar entries for CYP4F22. NCBI

14. Skin biopsy with electron microscopy (selected cases) – Shows reduced or abnormal lipid lamellae and corneocyte lipid envelope when needed. FEBS Journal

15. Epidermal lipid (ceramide) profiling – Specialized labs can measure low acylceramides, supporting the mechanism in CYP4F22 disease. PubMed Central

D) Electrodiagnostic / instrument-based physiology (limited but useful)

16. Corneometry (skin capacitance) – A small device uses electrical properties to estimate skin hydration; low values reflect dryness. (Methodology widely used in barrier research.) FEBS Journal

17. Skin impedance measurement – Electrical resistance of skin correlates with barrier integrity; lower integrity shows altered impedance. (Barrier testing concept.) FEBS Journal

18. Sudomotor/sweat testing in heat intolerance – If overheating is a concern, clinicians may assess sweating function to guide safety advice. (Clinical practice concept in ichthyosis.) NCBI

E) Imaging / optical tools

19. Dermoscopy – Magnified light tool to view scale patterns and fissures more clearly, aiding documentation and differential diagnosis. (Dermatologic imaging concept.) NCBI

20. In-vivo reflectance confocal microscopy or OCT (where available) – Noninvasive imaging can visualize stratum corneum architecture and scaling without a biopsy. (Research/advanced clinic concept.) FEBS Journal

Non-pharmacological treatments (therapies and others)

1. Daily soaking baths (10–15 min) – Soaks loosen thick scales and hydrate the skin. Pat dry and seal with ointment within 3 minutes to trap water. Purpose: soften scale, reduce itch and cracking. Mechanism: re-hydrates stratum corneum; lowers transepidermal water loss (TEWL). ERN Skin+1

2. Frequent emollients (petrolatum/occlusive ointments) – Apply several times daily, especially after bathing. Purpose: lock in moisture; reduce scaling and fissures. Mechanism: occlusion reduces TEWL and improves barrier function. Husk+1

3. Humidified environment (esp. for newborns/collodion) – Start higher humidity and gradually normalize as skin stabilizes. Purpose: prevent dehydration, overheating, and skin cracking. Mechanism: ambient humidity reduces water loss through impaired barrier. akademiska.se

4. Gentle manual scale removal – After soaking, use a soft cloth or baby brush; avoid aggressive scraping. Purpose: safe de-scaling. Mechanism: mechanical debulking of hyperkeratosis with minimal trauma. Husk

5. Bleach baths (very dilute, 1–2 times/week for recurrent infections) – Only as advised by a clinician. Purpose: reduce bacterial load and recurrent impetigo. Mechanism: dilute sodium hypochlorite decreases S. aureus colonization. PubMed Central

6. Eye lubrication (drops/ointments) for ectropion – Keeps corneas protected. Purpose: prevent exposure keratitis. Mechanism: artificial tear film compensates for poor lid coverage. firstskinfoundation.org

7. Sun and heat management – Loose, breathable clothing; avoid overheating. Purpose: reduce heat intolerance and skin water loss. Mechanism: minimizes sweat duct stress and TEWL. Husk

8. Nail and scalp care – Regular trimming and keratolytic shampoos as advised. Purpose: reduce scalp scale and nail discomfort. Mechanism: controlled keratolysis and moisturization. JAAD

9. Ear canal hygiene by clinicians – Periodic softening and professional debridement. Purpose: prevent plugging and hearing issues. Mechanism: removes adherent scale safely. Husk

10. Pain and itch plans – Use simple analgesics and cool compresses; discuss safe antihistamine use when needed. Purpose: improve sleep and quality of life. Mechanism: reduces symptom cycle that worsens barrier damage. ERN Skin

11. Psychosocial support – Education, support groups, school notes for skincare time. Purpose: reduce stress, improve adherence. Mechanism: addresses burden documented for congenital ichthyoses. Frontiers

12. Protect cracked areas with barrier dressings – Hydrocolloid or petrolatum gauze. Purpose: speed healing, prevent infection. Mechanism: moist wound healing. Husk

13. Safe keratolytic technique – Introduce acids (lactic/salicylic) slowly; avoid high-strength on infants or thin skin. Purpose: avoid irritation or salicylate toxicity. Mechanism: controlled corneocyte shedding. Medical Journals Sweden

14. Foot care for palmoplantar thickening – Podiatry debridement when needed. Purpose: prevent fissures and pain. Mechanism: mechanical reduction of hyperkeratosis. PubMed Central

15. Infection vigilance – Teach signs (oozing, honey crust, fever) and early care. Purpose: quick treatment lowers complications. Mechanism: prompt antimicrobial steps when needed. Husk

16. Newborn thermal and fluid monitoring – In hospital for collodion babies. Purpose: prevent dehydration and electrolyte problems. Mechanism: incubator humidity and close monitoring. akademiska.se

17. Ophthalmology referral for significant ectropion – Assess need for taping or surgery. Purpose: protect vision. Mechanism: specialist corneal protection plan. jaadcasereports.org

18. Dermatology genetic counseling – Family planning and carrier info. Purpose: informed decisions and early care. Mechanism: confirm CYP4F22 status and recurrence risk. NCBI

19. Structured skincare checklist – Morning/evening routines to enhance adherence. Purpose: consistent barrier support. Mechanism: habit-based care improves outcomes. Husk

20. Multidisciplinary care – Coordinate dermatology, neonatology, ophthalmology, ENT, plastics, pediatrics. Purpose: comprehensive support for complications. Mechanism: guideline-based team care. akademiska.se

---

Drug treatments

Important: No drug is FDA-approved specifically for ARCI5. Clinicians often use medications “off-label” to reduce scaling, redness, and infections. Below I list commonly used options, with FDA labels for the products (psoriasis/acne indications) and brief mechanisms; discuss with a dermatologist for individualized dosing and safety.

Systemic retinoids (most impactful for thick, generalized scale):

1. Acitretin (Soriatane®) – Oral retinoid that reduces thick scaling by normalizing skin cell growth and shedding. Typical psoriasis dosing is 10–25 mg daily (individualized; pregnancy prevention is critical for people who can become pregnant and must continue for 3 years after stopping). Side effects: dry lips/eyes, hair thinning, high lipids, liver enzyme changes; strict contraception and monitoring required. Used off-label in ichthyosis. FDA Access Data+1

2. Isotretinoin (Absorica®/Accutane®) – Oral retinoid; sometimes chosen when acitretin is unsuitable. Similar benefits and safety issues; pregnancy is absolutely contraindicated and iPLEDGE applies. Off-label for ichthyoses, with careful monitoring of liver, lipids, and mood. FDA Access Data+2FDA Access Data+2

Topical retinoids (for focal thick areas, lids/ectropion under expert care):

3. Tazarotene gel/cream (Tazorac®/Avage®) – Retinoid that thins scale and may help lid margin tightness when used by specialists. Can irritate; start low-frequency. Off-label for ichthyosis. FDA Access Data+1

Keratolytics & humectants (licensed for other dermatoses; commonly used in ichthyosis):

4. Ammonium lactate 12% (Lac-Hydrin®) – Hydrates and gently dissolves surface scale; sting is possible on cracks. Off-label for ichthyosis but widely used. FDA Access Data+1

5. Urea creams (20–40%) – Strong humectant/keratolytic that softens scale; avoid high-strength on infants/flexures. (FDA labeling exists for specific 40% urea products; use as directed.) FDA Access Data

6. Salicylic acid keratolytics – Help shed thick plaques; avoid large areas in young children due to salicylate toxicity risk. (OTC monograph class—follow label limits.) Medical Journals Sweden

Anti-inflammatory adjuncts (for fissures/eczema-like inflammation):

7. Super-potent topical steroids (e.g., clobetasol) – Short courses calm inflamed, fissured patches; not for chronic large-area use due to HPA-axis suppression and skin atrophy. Off-label to treat secondary inflammation in ichthyosis. FDA Access Data

8. Vitamin D analog (calcipotriene) – Sometimes used on thick plaques to normalize keratinization; irritation possible; avoid face/flexures; monitor for hypercalcemia if overused. Off-label in ichthyosis. FDA Access Data+1

Antimicrobials (when infection is present):

9. Topical antibiotics for localized impetigo (e.g., mupirocin; per clinician choice) – Short courses only; culture if recurrent. Purpose: treat superinfection that worsens scaling. (Use product per its FDA label for indicated infections.) Husk

10. Antiseptic strategies (dilute bleach baths) – See non-drug section; used under guidance to reduce recurrent infections. PubMed Central

Emerging/adjunct topical agents (off-label, case-level evidence):

11. Tapinarof cream – Aryl hydrocarbon receptor modulator; reports suggest benefit in palmoplantar hyperkeratosis; discuss risks/benefits; not ARCI-approved. PubMed Central

12. Other emollient actives (e.g., ceramide-rich moisturizers) – Over-the-counter but mechanistically aligned with barrier lipid needs. PubMed Central

For individualized dosing schedules and monitoring plans (lipids, liver, pregnancy prevention, eye care), follow the European/International ichthyosis management guidelines and partner with a dermatologist experienced in genodermatoses. PubMed+1

---

Dietary molecular supplements

Note: Supplements do not replace skincare or prescriptions. Evidence in ARCI is limited; suggestions below are mechanistic or extrapolated from barrier-function research. Discuss with a clinician and avoid megadoses.

1. Linoleic acid–rich omega-6 (e.g., safflower/sunflower oil with food) – Linoleic acid is an essential fatty acid critical for skin barrier ceramides. Deficiency causes scaly dermatitis that looks like ichthyosis; replacing it supports lipid mortar. Typical diet inclusion is safer than high capsules; people with lipid disorders should ask a doctor first. PubMed Central+1

2. Omega-3 fatty acids (ALA/EPA/DHA) – May reduce skin inflammation and improve dryness in some conditions; start with food sources (fish, flax). Mechanism: lipid mediator balance and barrier support. Check interactions with blood thinners. PubMed Central

3. Vitamin D3 – Helps epidermal differentiation and innate defense; low D is linked with worse barrier in other dermatoses. Use standard daily doses unless a clinician advises otherwise. PubMed Central+1

4. Nicotinamide (Vitamin B3 amide) – Supports barrier lipids and antimicrobial peptides; commonly used topically but oral forms are also studied in skin health. Avoid in severe liver disease unless approved. PubMed Central+1

5. L-serine (under research) – Precursor for sphingolipids; experimental work shows serine availability affects ceramide pathways; clinical evidence in ichthyosis is limited. Use only under medical advice. jlr.org

6. Zinc – Cofactor for skin healing and immunity; correct frank deficiency only (lab-guided), as excess zinc can cause copper deficiency. Husk

7. Biotin – May help brittle nails; skin benefit is limited unless a true deficiency exists. Avoid high doses before lab testing as it can interfere with assays. Husk

8. Vitamin E – Antioxidant support for dry, cracked skin in small studies; avoid high doses with anticoagulants. Husk

9. Probiotics (adjunct) – Evidence comes mostly from atopic dermatitis; mechanism is immune modulation and barrier effects. Benefits in ichthyosis are unproven; discuss case-by-case. bpspubs.onlinelibrary.wiley.com

10. Balanced dietary fats overall – Rather than single megadose supplements, a balanced intake of essential fats helps the skin produce the right ceramides. ScienceDirect

---

Immunity-booster / regenerative / stem-cell drugs

Straight talk: there are no FDA-approved “immunity boosters,” regenerative drugs, or stem-cell products for ARCI5. Some products on the market claim this, but FDA has repeatedly warned that such stem-cell/exosome offerings are unapproved and potentially dangerous. Here’s what’s important to know (with FDA sources):

1. Unapproved stem-cell/exosome products – FDA safety alerts warn of serious harms; these products are not approved for skin diseases like ichthyosis. Do not use outside regulated trials. U.S. Food and Drug Administration+1

2. Palifermin (Kepivance®) – A keratinocyte growth factor approved to reduce oral mucositis in certain cancer settings; no indication for skin barrier diseases and potential tumor-growth concerns. Not recommended for ARCI. FDA Access Data+1

3. Filgrastim (Neupogen®) – A white-cell growth factor for neutropenia; no role in ichthyosis. Using it for skin dryness would be inappropriate. FDA Access Data

4. Cord-blood/HCT/P products – FDA states you may not administer unapproved cellular products outside an IND or approval; these are not treatments for ichthyosis. U.S. Food and Drug Administration

5. Biologics for other conditions – Some biologics are approved for eczema or psoriasis, but they are not approved for ARCI, and evidence is limited. Use only in research or with expert guidance. Frontiers

6. Bottom line – If you see “stem-cell cures for ichthyosis,” treat them as red flags and check FDA/dermatology guidance first. U.S. Food and Drug Administration

---

Surgeries

1. Ectropion eyelid repair (skin grafts, tarsorrhaphy, or combined approaches) – For severe outward-turning eyelids that threaten the cornea. Surgery protects vision when lubrication alone is not enough. PubMed Central+2PubMed Central+2

2. Release of digital constriction bands (pseudoainhum) with Z-plasty or grafting – Rarely, tight “rings” can form around fingers/toes and risk auto-amputation; surgical release restores blood flow and function. PubMed Central+1

3. Full-thickness excision and grafting for severe palmoplantar keratoderma (selected cases) – Removes dense, painful plaques when conservative care fails. Medscape

4. Temporary eyelid procedures in infants (partial tarsorrhaphy/taping) – Protects the cornea while the skin improves with medical therapy. rbcp.org.br

5. Specialized debridement under anesthesia (ear canals, thick plaques) – For difficult areas where clinic debridement isn’t possible; improves hearing or mobility. Husk

---

Preventions

1. Moisturize many times daily; seal within 3 minutes of bathing. Husk

2. Use lukewarm, short baths; avoid hot showers that strip oils. Husk

3. Choose fragrance-free, gentle cleansers and laundry products. Husk

4. Wear breathable clothing; avoid overheating. Husk

5. Keep nails short to reduce scratching injuries. Husk

6. Learn infection signs; seek treatment early. Husk

7. Protect eyes with lubricants; arrange ophthalmology checks for lid issues. firstskinfoundation.org

8. Plan travel/humidity (portable humidifier, ointments on hand). Husk

9. Vaccinations per schedule; healthy skin lowers infection risk overall. Husk

10. Ask for written school/work care plans to support adherence. Frontiers

---

When to see a doctor

See a dermatologist or pediatrician promptly if you notice: spreading redness with oozing or fever; deep painful cracks that don’t improve; eye pain, light sensitivity, or vision changes; rapid swelling of fingers or toes; signs of dehydration or poor feeding in babies; new medicines causing sudden worsening; or major life events like pregnancy planning (retinoids are absolutely contraindicated). NCBI+2FDA Access Data+2

---

What to eat and what to avoid

Eat: a balanced diet rich in essential fats (e.g., fish, nuts/seeds, safflower/sunflower oil), vegetables, fruits, whole grains, and adequate protein—this supports skin repair and lipid production. Avoid: extreme low-fat diets (risk of essential fatty acid deficiency), excessive alcohol (worsens dryness), and mega-dose supplements without medical advice. Drink enough water; diet cannot “cure” ARCI5 but supports the skin from the inside. PubMed Central+1

---

Frequently asked questions

1) Is ARCI5 curable?
No. It is genetic and lifelong, but good daily care and, when needed, retinoids can greatly improve comfort and function. NCBI

2) Is ARCI5 dangerous?
The skin itself is not dangerous, but dehydration, infections, and eye problems can be serious—especially in infants—so prevention and early care matter. akademiska.se

3) Can moisturizers alone control it?
Many people do well with diligent skincare, but some need retinoids or keratolytics for thick scale. Husk

4) Why do doctors use “off-label” medicines?
Because no drug is FDA-approved for ARCI; retinoids and keratolytics are borrowed from psoriasis/acne care with careful monitoring. PubMed

5) Are retinoids safe?
They can be very effective, but require labs and strict pregnancy prevention (acitretin has a 3-year post-therapy contraception requirement; isotretinoin uses iPLEDGE).

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 06, 2025.